Background: Trophoblast cell surface antigen 2 (TROP2) has unclear clinical role in oral squamous cell carcinomas (OSCC). Here, we investigated the association of TROP2 immunoexpression with clinicopathological parameters and survival of OSCC patients. Subjects and Methods: Cancer-specific survival (CSS) and disease-free survival (DFS) were assessed in a cohort composed of 266 OSCC. An independent cohort with 88 OSCC samples matched with the normal oral tissue, as well as 17 metastatic lymph nodes, was used for validation. Results: Multivariate analysis showed TROP2 as an independent marker of favorable prognosis for both CSS (HR: 0.60, 95% CI: 0.40–0.90, p =.01) and DFS (HR: 0.57, 95% CI: 0.36–0.89, p =.01). Furthermore, TROP2 protein expression was significantly higher in morphologically normal tissues compared to primary tumors (p <.0001) and lymph node metastases (p =.001), and it was significantly associated with CSS (HR: 0.26, 95% CI: 0.09–0.74, p =.008) in the validation cohort. A pooled mRNA analysis performed on the Oncomine™ database confirmed the underexpression in OSCC compared with normal tissues (p =.014). Conclusions: In summary, our results point to a favorable prognostic significance of TROP2 overexpression in a large cohort of oral cancer patients, suggesting it as an attractive clinical marker.
|Fecha en línea anticipada||22 feb. 2021|
|Estado||Publicada - 2021|
|Publicado de forma externa||Sí|
Nota bibliográficaFunding Information:
This work was supported by grants from the Fundação de Amparo à Pesquisa do Estado de São Paulo ‐ FAPESP (2018/16077‐6 for RDC), and the Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq (303589/2019‐1). LMRP is supported by the Fundação de Amparo à Pesquisa do Estado de Minas Gerais ‐ FAPEMIG (APQ 00205.16 for LMRP), and. MRD (2017/26764‐8) is research fellow supported by FAPESP (2017/26764‐8)
© 2021 Wiley Periodicals LLC